Drugs / HN2301
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07333677 | Jan 2026 → Jun 2027 expected | Graves disease | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07556120 | May 2026 → May 2027 expected | generalized myasthenia gravis | Shenzhen MagicRNA Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06801119 | Mar 2025 → Dec 2027 expected | rheumatoid arthritis, scleroderma, systemic lupus erythematosus | Shenzhen MagicRNA Biotechnology Co., Ltd | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06965309 | Jan → Feb 2026 | myasthenia gravis | Shenzhen MagicRNA Biotechnology Co., Ltd | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | Shenzhen MagicRNA Biotechnology Co., Ltd | Results MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine. magicrna.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | Shenzhen MagicRNA Biotechnology Co., Ltd | MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine. magicrna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HN2301 | “Participants will receive 3 to 5 intravenous administrations of HN2301, given once every 2 days, according to the study dosing regimen.” NCT07333677 ↗ |
| Modality | Cell therapy | “This study aims to evaluate the safety and efficacy of HN2301, an in vivo CAR-T therapy” NCT07333677 ↗ |
| Target | CD19 | “via CD8 antibody-coated LNP delivery of CD19 CAR-mRNA” NCT07333677 ↗ |